We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

118 hedge funds and large institutions have $561M invested in Nurix Therapeutics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

173,900% more call options, than puts

Call options by funds: $1.74M | Put options by funds: $1K

150% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 8

122% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 23

11% more funds holding

Funds holding: 106 → 118 (+12)

1% less capital invested

Capital invested by funds: $568M → $561M (-$7.2M)

8.58% less ownership

Funds ownership: 100.1% → 91.52% (-8.6%)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
118
Holders Change
+12
Holders Change %
+11.32%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
20
Increased
51
Reduced
23
Closed
8
Calls
$1.74M
Puts
$1K
Net Calls
+$1.74M
Net Calls Change
-$400K

Top Buyers

1
AIM
ARK Investment Management
Florida
+$8.04M
2
Goldman Sachs
Goldman Sachs
New York
+$7.81M
3
WA
Wasatch Advisors
Utah
+$6.24M
4
BlackRock
BlackRock
New York
+$5.82M
5
N
Nuveen
North Carolina
+$3.61M

Top Sellers

1
TGI
TRV GP III
Massachusetts
-$24.4M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$16.1M
3
EAM
Eventide Asset Management
Massachusetts
-$14.6M
4
FCMI
Foresite Capital Management IV
California
-$8.58M
5
SCM
Soleus Capital Management
Connecticut
-$7.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
Manulife (Manufacturers Life Insurance)
51
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$787K -$7.8K -493 -0.8%
D.E. Shaw & Co
52
D.E. Shaw & Co
New York
$782K +$950K +60,014 New
JCIA
53
Jackson Creek Investment Advisors
Colorado
$716K -$1.3K -82 -0.1%
RJA
54
Raymond James & Associates
Florida
$666K +$155K +9,800 +24%
CAM
55
ClariVest Asset Management
California
$648K – – –
Susquehanna International Group
56
Susquehanna International Group
Pennsylvania
$640K +$528K +33,378 +212%
California State Teachers Retirement System (CalSTRS)
57
California State Teachers Retirement System (CalSTRS)
California
$617K +$1.22K +77 +0.2%
AP
58
AtonRa Partners
Switzerland
$611K -$36.4K -2,302 -5%
JF
59
Jump Financial
Illinois
$571K +$91.8K +5,800 +15%
Jennison Associates
60
Jennison Associates
New York
$563K -$8.75K -553 -1%
TD Asset Management
61
TD Asset Management
Ontario, Canada
$558K – – –
UBS Group
62
UBS Group
Switzerland
$545K -$278K -17,550 -30%
State of Wisconsin Investment Board
63
State of Wisconsin Investment Board
Wisconsin
$448K +$152K +9,602 +39%
New York State Common Retirement Fund
64
New York State Common Retirement Fund
New York
$404K +$2.36K +149 +0.5%
Aberdeen Group
65
Aberdeen Group
United Kingdom
$398K +$483K +30,537 New
Mariner
66
Mariner
Kansas
$391K +$1.73K +109 +0.4%
CS
67
Credit Suisse
Switzerland
$376K +$209K +13,231 +85%
JP Morgan Chase
68
JP Morgan Chase
New York
$368K -$1.6M -101,251 -78%
Blackstone Inc
69
Blackstone Inc
New York
$353K +$162K +10,257 +61%
ECM
70
ExodusPoint Capital Management
New York
$338K +$411K +25,954 New
TI
71
Trexquant Investment
Connecticut
$326K +$232K +14,636 +141%
Mirae Asset Global Investments
72
Mirae Asset Global Investments
South Korea
$316K +$224K +14,141 +140%
SG Americas Securities
73
SG Americas Securities
New York
$311K -$164K -10,348 -30%
XT
74
XTX Topco
Cayman Islands
$311K +$378K +23,879 New
MIM
75
MetLife Investment Management
New Jersey
$303K – – –
1 2
3
4 5

NRIX Hedge Fund Activity: Q3 2022 in Review

118 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2022, worth a combined $561M — down 1.3% from $568M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new NRIX positions and 8 closed out — a net gain of 12 holders — while 51 added to existing stakes and 23 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $8.04M. The largest seller was TRV GP III, exiting entirely with an estimated $24.4M sold.

  • 118 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2022, up from 106 in Q2 2022.
  • Funds reported $561M of Nurix Therapeutics stock for Q3 2022, down 1.3% quarter-over-quarter.
  • 20 funds opened new Nurix Therapeutics positions in Q3 2022 and 8 closed out, a net change of +12 holders.
  • The largest Nurix Therapeutics buyer in Q3 2022 was ARK Investment Management, an estimated $8.04M added.
  • The largest Nurix Therapeutics seller in Q3 2022 was TRV GP III, an estimated $24.4M sold.

Based on aggregated 13F filings for Q3 2022.